September 19, 2012
Webinar
Managing Intellectual Property (MIP)
LexisNexis
Finnegan partner Eric Raciti will participate in a panel discussion regarding the impact of the Prometheus decision on the eligibility question, including what guidance it may provide with respect to the eligibility of gene patents, how the PTO is likely to react to the decision, and the impact the decision will have on the medical field. The Managing IP and LexisNexis co-hosted program will take place at 11:00 a.m. EDT. For more information, or to register, please see MIP’s website.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.